Vol 31, No 9 (September 2010): Acta Pharmacologica Sinica(Special Feature:Celebrating the 30th Anniversary of APS)

Review

Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels in the regulation of midbrain dopamine systems Pages:1036
Hong-yuan Chu, Xuechu Zhen
Recent advances in (patho)physiology of astroglia Pages:1044
Alexei Verkhratsky, Vladimir Parpura
Genetics of stroke Pages:1055
Jin-min Guo, Ai-jun Liu, Ding-feng Su
The role of κ-opioid receptor activation in mediating antinociception and addiction Pages:1065
Yu-hua Wang, Jian-feng Sun, Yi-min Tao, Zhi-qiang Chi, Jing-gen Liu
Inhibitory role of oxytocin in psychostimulant-induced psychological dependence and its effects on dopaminergic and glutaminergic transmission Pages:1071
Jing-yu Yang, Jia Qi, Wen-yan Han, Fang Wang, Chun-fu Wu
AMPK in cardiovascular health and disease Pages:1075
Najeeb A Shirwany, Ming-Hui Zou
Hypoxia inducible factor 1 (HIF-1) and cardioprotection Pages:1085
Demet Tekin, Ali D Dursun, Lei Xi
COX-mediated endothelium-dependent contractions: from the past to recent discoveries Pages:1095
Michael Sze-Ka Wong, Paul Michel Vanhoutte
Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias Pages:1103
Stavros Apostolakis, Virginia Amanatidou, Demetrios A Spandidos
Caloric restriction and heart function: is there a sensible link? Pages:1111
Xuefeng Han, Jun Ren
Cathelicidins in inflammation and tissue repair: Potential therapeutic applications for gastrointestinal disorders Pages:1118
William Ka Kei Wu, Clover Ching Man Wong, Zhi Jie Li, Lin Zhang, Shun Xiang Ren, Chi Hin Cho
Type I natural killer T cells: naturally born for fighting Pages:1123
Jin-quan Tan, Wei Xiao, Lan Wang, Yu-ling He
Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis Pages:1133
Juan Jin, Yan Chang, Wei Wei
Fragile privileges: autoimmunity in brain and eye Pages:1141
Hartmut Wekerle, De-ming Sun
Purinergic signaling: a novel mechanism in immune surveillance Pages:1149
Lin Mei, Wei Du, Wei Gao, Qi-bing Mei
Autophagic pathways as new targets for cancer drug development Pages:1154
Bo Liu, Yan Cheng, Qian Liu, Jin-ku Bao, Jin-Ming Yang
Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma Pages:1165
Leilei Chen, Tim Hon Man Chan, Xin-yuan Guan
Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics Pages:1172
Jin-xue He, Chun-hao Yang, Ze-hong Miao
Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy Pages:1181
Ming-Hai Wang, Snehal S Padhye, Sunny Guin, Qi Ma, Yong-qing Zhou
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system Pages:1189
De-xin Kong, Takao Yamori
Research and development of next generation of antibody-based therapeutics Pages:1198
Jing Li, Zhenping Zhu
The role of p53 in cell metabolism Pages:1208
Xing-ding Zhang, Zheng-hong Qin, Jin Wang
Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors Pages:1213
Dong-Soon Im

Original Article

Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells Pages:1223
Sujit Nair, Avantika Barve, Tin-Oo Khor, Guo-xiang Shen, Wen Lin, Jefferson Y Chan, Li Cai, Ah-Ng Kong